Artiva Biotherapeutics, Inc.ARTVNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+16.5%
5Y CAGR+38.1%
Year-over-Year Change
Research and development spending
3Y CAGR
+16.5%/yr
Annual compound
5Y CAGR
+38.1%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
5x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $69.54M | +38.2% |
| 2024 | $50.33M | +0.2% |
| 2023 | $50.25M | +14.2% |
| 2022 | $43.98M | +3.7% |
| 2021 | $42.41M | +206.3% |
| 2020 | $13.85M | - |